Rigel Pharmaceuticals, Inc.: Company Profile and SWOT Analysis by ICDResearch

VIEWS: 9 PAGES: 32

More Info
									Rigel Pharmaceuticals, Inc.

_________________________________________________________________________________



Rigel Pharmaceuticals, Inc.                                                        Financial Snapshot

                                                                                   Operating Performance
Fast Facts
                                       1180 Veterans Blvd., South San Francisco,   The company reported revenues of US$125.00 million
Headquarters Address
                                       94080,United States of America              during 2010, with a CAGR of 39.01% during 2006–
                                                                                   2010. Its revenue grew at an annual rate of
Telephone                              + 1 650 6241100
                                                                                   16566.67% over the previous fiscal year. In 2010, the
                                                                                   company recorded an operating margin of 28.25%, as
Fax                                    + 1 650 6241101                             against -14938.27% in 2009.

Website                                www.rigel.com
                                                                                   Revenue and Margins
Ticker Symbol, Stock Exchange          RIGL, NASDAQ

Number of Employees                    145

Fiscal Year End                        December

Revenue (in US$ million)               125.00




SWOT Analysis

Strengths                              Weaknesses

Focus on R&D activities                Lack of manufacturing facilities

Strategic collaborations               Overdependence on single customer

Strong top-line performance

Opportunities                          Threats

Changing demographics                  Competitive environment

Growing prevalence of cancer           Outcome of clinical trials

                                       Tightening of the FDA’s regulatory
Increasing of healthcare expenditure
                                       oversight




___________________________________________________________________________________________

Rigel Pharmaceuticals, Inc. - SWOT Profile                                                                                Page 1
Rigel Pharmaceuticals, Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
2     Analysis of Key Performance Indicators ............................................................................................... 7
    2.1       Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................7
    2.2       Key Financial Performance Indicators .................................................................................................................10
      2.2.1       Revenue and Operating Profit .........................................................................................................................10
      2.2.2       Asset, Liabilities and Capex .............................................................................................................................11
      2.2.3       Solvency ..........................................................................................................................................................12
      2.2.4       Valuation ..........................................................................................................................................................13
    2.3       Key Competitors ...................................................................................................................................................14
3     Mergers & Acquisitions and Partnerships ........................................................................................... 15
    3.1       M&A and Partnerships Strategy ...........................................................................................................................15
4     Recent Developments ........................................................................................................................... 18
5     SWOT Analysis ...................................................................................................................................... 20
    5.1       SWOT Analysis - Overview ..................................................................................................................................20
    5.2       Strengths ..............................................................................................................................................................20
    5.3       Weaknesses .........................................................................................................................................................20
    5.4       Opportunities ........................................................................................................................................................21
    5.5       Threats .................................................................................................................................................................21
6     Rigel Pharmaceuticals, Inc. - Company Statement ............................................................................. 23
7     History .................................................................................................................................................... 25
8     Rigel Pharmaceuticals, Inc. - Key Employees ..................................................................................... 26
9     Key Employee Biographies................................................................................................................... 27
10    Appendix ................................................................................................................................................ 28
    10.1      Methodology .........................................................................................................................................................28
    10.2      Ratio Definitions ...................................................................................................................................................28
    10.3      Disclaimer.............................................................................................................................................................32




___________________________________________________________________________________________

Rigel Pharmaceuticals, Inc. - SWOT Profile                                                                                                                                  Page 2
Rigel Pharmaceuticals, Inc.

__________________________________________________________________________________________



List of Tables

Table 1: Major Products and Services ..................................................................................................................................6
Table 2: Key Ratios - Annual ..................................................................................................................................................7
Table 3: Key Ratios - Interim ..................................................................................................................................................9
Table 4: Key Capital Market Indicators ..................................................................................................................................9
Table 5: Rigel Pharmaceuticals, Inc., History .......................................................................................................................25
Table 6: Rigel Pharmaceuticals, Inc., Key Employees .........................................................................................................26
Table 7: Key Employee Biographies ....................................................................................................................................27




___________________________________________________________________________________________

Rigel Pharmaceuticals, Inc. - SWOT Profile                                                                                                                           Page 3
Rigel Pharmaceuticals, Inc.

__________________________________________________________________________________________


List of Figures

Figure 1: Revenue and Operating Profit ..................................
								
To top